Researchers from the University of California San Francisco have validated volumetric breast density software technique when compared to MRI results. In “Agreement of Mammographic Measures of Volumetric Breast Density to MRI” researchers compared several automated methods of assessing volumetric breast density from digital screening mammograms and evaluated their agreement with a quantitative volumetric MRI-based technique. VolparaDensity software from Matakina International demonstrated the highest correlation to MRI findings for fibroglandular volume, outperforming other commercial vendors.
“We are delighted that these independent results continue to validate VolparaDensity’s volumetric breast density versus ground truth,” said Ralph Highnam, CEO, Matakina International.
VolparaDensity evaluates density from both digital mammography and tomosynthesis images to help identify patients who might require further screening. The software has been cleared by the FDA, HealthCanada, and the TGA, and is CE-marked. According to Matakina, more than 2 million women have had their breast density analyzed with VolparaDensity.